Article Sidebar

PDF
Date Published: 25/06/2024
Online Published: 22/05/2024
Abstract Views: 79
Views PDF: 46
DOI: https://doi.org/10.58490/ctump.2024i7.2976
Issue
No. 7 (2024): SỐ TIẾNG ANH
Section
Article
How to Cite
Huynh, H. K., Nguyen, D. N. C., & Tran, C. L. (2024). IMMUNOGLOBULIN E IN PEDIATRIC ASTHMA: ADVANCES IN UNDERSTANDING AND MANAGEMENT. Cantho Journal of Medicine and Pharmacy, 7, 170-180. https://doi.org/10.58490/ctump.2024i7.2976

IMMUNOGLOBULIN E IN PEDIATRIC ASTHMA: ADVANCES IN UNDERSTANDING AND MANAGEMENT

Hoang Khang Huynh1, Dinh Nguyen Chuong Nguyen1, Cong Ly Tran1,
1 Can Tho University of Medicine and Pharmacy

Main Article Content

Abstract

 Asthma, a pervasive chronic inflammatory ailment of the respiratory system, remains a global health conundrum. The Global Burden of Disease Study (GBD) of 2019 underscores its widespread impact, revealing that asthma afflicts 262 million individuals worldwide, translating into an age-standardized prevalence of 3,416 per 100,000 population. The incidence among children is particularly alarming, with nearly 14% of the global pediatric population diagnosed with the condition. This statistic positions asthma as the foremost chronic respiratory disease among children, a trend that is on the rise, especially across Asia and Europe, as evidenced by the International Study of Asthma and Allergies in Childhood (ISAAC). Characterized by variable airflow limitation, bronchial hyperresponsiveness, excessive mucus production, and airway inflammation leading to airway constriction, asthma’s multifaceted nature complicates its management. In the realm of immunology, Immunoglobulin E (IgE) has been identified as a pivotal player. Recognized officially as the fifth class of serum immunoglobulins during the 1968 WHO International Reference Center for Immunoglobulins conference in Lausanne, IgE’s crucial role in the pathophysiology of asthma has been rigorously studied. Serum IgE levels, both total and specific, have been proven instrumental in the diagnosis, treatment, and prevention of pediatric asthma. The landmark approval of Omalizumab by the US Food and Drug Administration in 2003 heralded a new era in the biologic management of asthma, targeting children aged six and above. This was followed by the development of Ligelizumab and Quilizumab, innovative anti-IgE medications currently under investigation for their potential to alleviate symptoms and decelerate the disease’s progression. The integration of Allergy Immunotherapy (AIT) alongside monoclonal antibody therapies like Omalizumab, Ligelizumab, and Quilizumab signifies a monumental shift toward personalized medicine in asthma care. These advances promise not only to ameliorate the quality of life for pediatric asthma patients but also to redefine the landscape of asthma management. Nonetheless, the quest for enhanced treatment modalities for young asthmatics necessitates further in-depth research. The burgeoning field of anti-IgE therapy, in concert with AIT, is poised to set new benchmarks in pediatric asthma management, steering us towards a future where asthma’s grip on children’s health is significantly loosened.

Article Details

Keywords

IgE, allergy, pediatric asthma, Omalizumab, Allergen Immunotherapy (AIT)

References

1. Dharmage S.C., Perret J.L., Custovic A. Epidemiology of Asthma in Children and Adults. Frontiers in Pediatrics. 2019.7, 246. https://doi.org/10.3389/fped.2019.00246.
2. The Global Asthma Report 2022. The International Journal of Tuberculosis and Lung Disease. 2022.26(1), 1-104. https://doi.org/10.5588/ijtld.22.1010.
3. Martin J., Townshend J., Brodlie M. Diagnosis and management of asthma in children. BMJ Paediatrics Open. 2022.6(1), e001277. https://doi.org/10.1136/bmjpo-2021-001277.
4. Chang M.L., Cui C., Liu Y.H., Pei L.C., Shao B. Analysis of total immunoglobulin E and specific immunoglobulin E of 3,721 patients with allergic disease. Biomedical Reports. 2015.3(4), 573-577. https://doi.org/10.3892/br.2015.455.
5. Khasawneh R., Hiary M., Abadi B., Salameh A., Moman S. Total and Specific Immunoglobulin E for Detection of Most Prevalent Aeroallergens in a Jordanian Cohort. Medical Archives. 2019.73(4), 272. https://doi.org/10.5455/medarh.2019.73.272-275.
6. Santus P., Saad M., Damiani G., Patella V., Radovanovic D. Current and future targeted therapies for severe asthma: Managing treatment with biologics based on phenotypes and biomarkers. Pharmacological Research. 2019.146, 104296. https://doi.org/10.1016/j.phrs.2019.104296.
7. Ahmad Al Obaidi A.H., Mohamed Al Samarai A.G., Yahya Al Samarai A.K., Al Janabi J.M. The Predictive Value of IgE as Biomarker in Asthma. Journal of Asthma. 2008.45(8), 654-663. https://doi.org/10.1080/02770900802126958.
8. Phipatanakul W., Mauger D.T., Guilbert T.W., Bacharier L.B., Durrani S., et al. Preventing Asthma in High Risk Kids (PARK) with Omalizumab: Design, Rationale, Methods, Lessons Learned and Adaptation. Contemporary clinical trials. 2021.100, 106228. https://doi.org/10.1016/j.cct.2020.106228.
9. Kuruvilla M.E., Lee F.E.H., Lee G.B. Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease. Clinical reviews in allergy & immunology. 2019.56(2), 219-233. https://doi.org/10.1007/s12016-018-8712-1.
10. Hamilton D., Lehman H. Asthma Phenotypes as a Guide for Current and Future Biologic Therapies. Clinical Reviews in Allergy & Immunology. 2020.59(2), 160-174. https://doi.org/10.1007/s12016-019-08760-x.
11. Colas L., Magnan A., Brouard S. Immunoglobulin E response in health and disease beyond allergic disorders. Allergy. 2022.77(6), 1700-1718. https://doi.org/10.1111/all.15230.
12. Ribatti D. The discovery of immunoglobulin E. Immunology Letters. 2016.171, 1-4. https://doi.org/10.1016/j.imlet.2016.01.001.
13. Platts-Mills T.A.E., Heymann P.W., Commins S., Woodfolk J.A. The discovery of IgE 50 years on. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2016.116(3), 179-182. https://doi.org/10.1016/j.anai.2016.01.003.
14. Johansson S.G.O. The discovery of IgE. Journal of Allergy and Clinical Immunology. 2016.137(6), 1671-1673. https://doi.org/10.1016/j.jaci.2016.04.004.
15. Lama M., Chatterjee M., Chaudhuri T.K. Total Serum Immunoglobulin E in Children with Asthma. Indian Journal of Clinical Biochemistry. 2013.28(2), 197-200. https://doi.org/10.1007/s12291-012-0247-2.
16. Akar-Ghibril N., Casale T., Custovic A., Phipatanakul W. Allergic Endotypes and Phenotypes of Asthma. The Journal of Allergy and Clinical Immunology: In Practice. 2020.8(2), 429-440. https://doi.org/10.1016/j.jaip.2019.11.008.
17. Satwani H., Rehman A., Ashraf S., Hassan A. Is Serum Total IgE levels a good predictor of Allergies in Children? J Pak Med Assoc. 2009.59(10).
18. Shamji M.H., Valenta R., Jardetzky T., Verhasselt V., Durham S.R., et al. The role of allergenspecific IgE, IgG and IgA in allergic disease. Allergy. 2021.76(12), 3627-3641. https://doi.org/10.1111/all.14908.
19. Shamji M.H., Valenta R., Jardetzky T., Verhasselt V., Durham S.R., et al. The role of allergenspecific IgE, IgG and IgA in allergic disease. Allergy. 2021.76(12), 3627-3641. https://doi.org/10.1111/all.14908.
20. Thomas D., McDonald V.M., Pavord I.D., Gibson P.G. Asthma remission: what is it and how can it be achieved? The European Respiratory Journal. 2022.60(5), 2102583. https://doi.org/10.1183/13993003.02583-2021.
21. Hammad H., Lambrecht B.N. The basic immunology of asthma. Cell. 2021.184(6), 1469-1485. https://doi.org/10.1016/j.cell.2021.02.016.
22. Froidure A., Mouthuy J., Durham S.R., Chanez P., Sibille Y., et al. Asthma phenotypes and IgE responses. European Respiratory Journal. 2016.47(1), 304-319. https://doi.org/10.1183/13993003.01824-2014.
23. Ramphul M., Lo D.K.H., Gaillard E.A. Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction. Journal of Asthma and Allergy. 2021.14, 525-538. https://doi.org/10.2147/JAA.S265657.
24. Licari A., Marseglia G.L. Current and future challenges in pediatric severe asthma. Current Medical Research and Opinion. 2018.34(5), 943-944. https://doi.org/10.1080/03007995.2018.1439463.
25. Stokes J.R., Casale T.B. Characterization of asthma endotypes: implications for therapy. Annals of Allergy, Asthma & Immunology. 2016.117(2), 121-125. https://doi.org/10.1016/j.anai.2016.05.016.
26. Licari A., Manti S., Chiappini E., Ciprandi G., Marseglia G.L. Severe asthma in children: Current goals and unmet needs. Pediatric Allergy and Immunology. 2020.31(S24), 40-42. https://doi.org/10.1111/pai.13168.
27. McGregor M.C., Krings J.G., Nair P., Castro M. Role of Biologics in Asthma. American Journal of Respiratory and Critical Care Medicine. 2019.199(4), 433-445. https://doi.org/10.1164/rccm.201810-1944CI.
28. Chung K.F. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. Journal of Internal Medicine. 2016.279(2), 192-204. https://doi.org/10.1111/joim.12382.
29. Varricchi G., Ferri S., Pepys J., Poto R., Spadaro G., et al. Biologics and airway remodeling in severe asthma. Allergy. 2022.77(12), 3538-3552. https://doi.org/10.1111/all.15473.
30. Licari A., Manti S., Castagnoli R., Parisi G.F., Salpietro C., et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatric Drugs. 2019.21(4), 215-237. https://doi.org/10.1007/s40272-019-00345-7.
31. Sardon-Prado O., Diaz-Garcia C., Corcuera-Elosegui P., Korta-Murua J., Valverde-Molina J., et al. Severe Asthma and Biological Therapies: Now and the Future. Journal of Clinical Medicine. 2023.12(18), 5846. https://doi.org/10.3390/jcm12185846.
32. Schepel I.R.M., Banzon T.M., Phipatanakul W. Future of biologics in pediatric asthma. Annals of Allergy, Asthma & Immunology. 2024.132(1), 13-20. https://doi.org/10.1016/j.anai.2023.08.597.
33. Trischler J., Bottoli I., Janocha R., Heusser C., Jaumont X., et al. Ligelizumab treatment for severe asthma: learnings from the clinical development programme. Clinical & Translational Immunology. 2021.10(3), e1255. https://doi.org/10.1002/cti2.1255.
34. Gasser P., Tarchevskaya S.S., Guntern P., Brigger D., Ruppli R., et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab.
Nature Communications. 2020.11, 165. https://doi.org/10.1038/s41467-019-13815-w.
35. Harris J.M., Maciuca R., Bradley M.S., Cabanski C.R., Scheerens H., et al. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respiratory Research. 2016.17(1), 29. https://doi.org/10.1186/s12931-016-0347-2.
36. Zemelka-Wiacek M., Agache I., Akdis C.A., Akdis M., Casale T.B., et al. Hot topics in allergen immunotherapy, 2023: Current status and future perspective. Allergy. n/a(n/a). https://doi.org/10.1111/all.15945.
37. Diamant Z., Van Maaren M., Muraro A., Jesenak M., Striz I. Allergen immunotherapy for allergic asthma: The future seems bright. Respiratory Medicine. 2023.210, 107125. https://doi.org/10.1016/j.rmed.2023.107125.
38. Caimmi D., Demoly P. A review of allergen immunotherapy in asthma. Allergy and Asthma Proceedings. 2022.43(4), 310-313. https://doi.org/10.2500/aap.2022.43.210113.